Abstract:Background and Purpose NLRP3 inflammasome activation is involved in many inflammatory diseases, however, no small‐molecule inhibitors of NLRP3 have been clinically used so far. Discovery of natural NLRP3 inhibitors may be beneficial to the design and development of molecules targeting NLRP3. Alantolactone (ALA) is a natural compound isolated from a traditional Chinese medicinal plant with anti‐inflammatory activity, but the precise target of ALA remains unclear. Experimental Approach The inhibitory activity of 150 natural compounds against NLRP3‐driven IL‐1β production was screened in macrophages. Mice models of gouty arthritis and acute lung injury were used to determine the efficacy of the potential compound. Key Results Among 150 compounds in an in‐house natural products bank, ALA was found to possess the highest inhibitory activity against LPS + ATP‐induced IL‐1β production in macrophages. We demonstrated that ALA suppressed the IL‐1β secretion, the caspase‐1 activation, and pyroptosis in LPS + ATP‐challenged macrophages. Further studies showed that ALA directly bound to the NACHT domain of NLRP3 to inhibit the activation and assembly of NLRP3 inflammasome. The molecular simulation showed that Arg335 in NLRP3 might be a critical residue for ALA binding, leading to suppression of NLRP3‐NEK7 interaction. The in vivo studies validated that ALA significantly alleviated NLRP3‐driven inflammatory diseases, including acute lung injury and gouty arthritis. Conclusion and Implications In summary, we identified ALA as a natural inhibitor of NLRP3 inflammasome by directly targeting NLRP3 NACHT domain. ALA shows great potential in the treatment of NLRP3‐driven diseases and the development of novel NLRP3 inhibitors.

Discovery of alantolactone as a natural NLRP3 inhibitor to alleviate NLRP3‐driven inflammatory diseases in mice

Discovery of NLRP3 Inhibitors Using Machine Learning: Identification of a Hit Compound to Treat NLRP3 Activation-Driven Diseases.

Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice

Discovery of novel NLRP3 inhibitors based on machine learning and physical methods

New Applications of Clioquinol in the Treatment of Inflammation Disease by Directly Targeting Arginine 335 of NLRP3

Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury

Chloranthalactone B covalently binds to the NACHT domain of NLRP3 to attenuate NLRP3-driven inflammation

Aloperine alleviates lipopolysaccharide-induced acute lung injury by inhibiting NLRP3 inflammasome activation

Glycyrrhetinic acid alleviates acute lung injury by PI3K/AKT suppressing macrophagic Nlrp3 inflammasome activation

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Identification of NLRP3 as a covalent target of 1,6-O,O-diacetylbritannilactone against neuroinflammation by quantitative thiol reactivity profiling (QTRP)

Discovery, Total Synthesis, and Anti‐inflammatory Evaluation of Naturally Occurring Naphthopyrone‐Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors

Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Inhibition of the NLRP3 Inflammasome Activation by Manoalide Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.